Conducting Clinical Risk Assessments for Visible Particulate Matter in Parenteral Preparations

Reference

1. 1.↵
   <1> Injections. U.S. Pharmacopeial Convention: Rockville, MD. 39-NF35 S2. Official beginning May 1, 2017.
2. 2.↵
   1. Langille S. E.

   Particulate Matter in Injectable Drug Products. J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.

   OpenUrl
3. 3.↵
   1. Bukofzer S.,
   2. Ayres J.,
   3. Chavez A.,
   4. Devera A.,
   5. Miller J.,
   6. Ross D.,
   7. Shabushnig J.,
   8. Vargo S.,
   9. Watson H.,
   10. Watson R.

   Industry Perspectives on the Medical Risk of Visible Particles in Injectable Drug Products. J. Pharm. Sci. Technol. 2015, 69 (1), 123–139.

   OpenUrl
4. 4.↵
   The International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Q8(R2) Pharmaceutical Development. Geneva, Switzerland, 2009.
5. 5.↵
   The International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Q9 Quality Risk Management. Geneva, Switzerland, 2006.
6. 6.↵
   The International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Q10 Pharmaceutical Quality Systems. Geneva, Switzerland, 2008.
7. 7.↵
   Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs. Code of Federal Regulations, Section 210, Title 21, Vol. 4, 2017.
8. 8.↵
   Current Good Manufacturing Practice for Finished Pharmaceuticals. Code of Federal Regulations, Section 211, Title 21, Vol. 4, 2017.
9. 9.↵
   <788> Particulate Matter in Injections. Pharmacopeial Convention: Rockville, MD. 39-NF35 S2. Official beginning May 1, 2017.
10. 10.↵
    1. Shtulman A.

    Scienceblind: Why Our Intuitive Theories About the World are so Often Wrong; Basic Books: New York, 2017 pp. 4–5.
11. 11.↵
    1. Madsen R. E.,
    2. Cherris R. T.,
    3. Shabushnig J. G.,
    4. Hunt D. G.

    Visible Particulates in Injections—A History and a Proposal to Revise USP General Chapter Injections <1>. Pharmacopeial Forum 2009, 35 (5), 1383–1387.

    OpenUrl
12. 12.↵
    Drug Alert. Class 4 Medicines Defect Information. MHRA. Pemetrexed 25 mg/ml Concentrate for solution for infusion. Ref: MDR 81-05/16. 16 June 2016.
13. 13.↵
    1. Shabushnig J. G,
    2. Melchore J. A.,
    3. Geiger M.,
    4. Chrai S.,
    5. Gerger M. E.

    A Proposed Working Standard for Validation of Particulate Inspection in Sterile Solutions. PDA Annual Meeting. Philadelphia, PA. 1995.
14. 14.↵
    <790> Visual Inspection of Injections. Pharmacopeial Convention: Rockville, MD. 39-NF35 S2. Official beginning May 1, 2017.
15. 15.↵
    1. Knapp J. Z.,
    2. Kushner H. K.

    Generalized Methodology for Evaluation of Parenteral Inspection Procedures. J. Pharm. Sci. Technol. 1980, 34 (1), 14–61.

    OpenUrl
16. 16.↵
    <787> Subvisible Particulate Matter in Therapeutic Protein Injections. Pharmacopeial Convention: Rockville, MD. 39-NF35 S2. Official beginning May 1, 2017.
17. 17.↵
    <789> Particulate Matter in Ophthalmic Solutions. Pharmacopeial Convention: Rockville, MD. 39-NF35 S2. Official beginning May 1, 2017.
18. 18.↵
    Identification and Classification of Nonconformities in Molded and Tubular Glass Containers for Pharmaceutical Manufacturing: Covering Ampoules, Bottles, Cartridges, Syringes and Vials. Technical Report No. 43 (Revised 2013). Parenteral Drug Association. Bethesda, MD. 2013.
19. 19.↵
    1. Shabushnig J.

    Particulate Matter and Visual Inspection: Industry Trends 2015. Parenteral Drug Association. Bethesda, MD. 2015.
20. 20.↵
    1. Aldrich S. D.,
    2. Cherris R. T.,
    3. Shabushnig J. G.

    Visual Inspection and Particulate Control; DHI Publishing, LLC: River Grove, 2016.
21. 21.↵
    <1790> Visual Inspection of Injections. Pharmacopeial Convention: Rockville, MD. 39-NF35 S2. Official beginning May 1, 2017.
22. 22.↵
    1. Beuchat L. R.

    Influence of Water Activity on Growth, Metabolic Activities and Survival of Yeasts and Molds. J. Food Prot. 1983, 46 (2), 135–141.

    OpenUrl
23. 23.↵
    1. Dempsey G.,
    2. Webber G. S.

    Hazards of Particle Injection. The Pharmaceutical J. 1983, 63–64.
24. 24.↵
    1. Larsen S.T.,
    2. Lund R.M.,
    3. Nielsen G.D.,
    4. Thygesen P.,
    5. Poulsen O.M.

    Adjuvant Effect of di-n-butyl-, di-n-octyl-, di-iso-nonyl-and di-isodecyl phthalate in a Subcutaneous Injection Model Using BALB/c Mice. 2002, Pharmacol. Toxicol. 91 (5), 264–72.

    OpenUrlPubMed
25. 25.↵
    1. Bailey L. O.,
    2. Lippiatt S.,
    3. Biancanello F. S.,
    4. Ridder S. D.,
    5. Washburn N. R.

    The Quantification of Cellular Viability and Inflammatory Response to Stainless Steel Alloys. Biomaterials. 2005, 26 (26), 5296–5302.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Greenblatt D. J.,
    2. Allen M. D.

    Intramuscular Injection-Site Complications. JAMA. 1978, 240 (6), 542–44.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Allcutt D. A.,
    2. Lort D.,
    3. McCollum C. N.

    Final Inline Filtration for Intravenous Infusions: A Prospective Hospital Study. Br. J. Surg. 1983, 70 (2), 111–113.

    OpenUrlPubMedWeb of Science
28. 28.↵
    1. Puntis J. W.,
    2. Wilkins K. M.,
    3. Ball P. A.,
    4. Rushton D. I.,
    5. Booth I. W.

    Hazards of Parenteral Treatment: Do Particles Count? Arch. Dis. Child. 1992, 67 (12), 1475–1477.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Liu J. F.,
    2. Su Z. K.,
    3. Ding W. X.

    Quantitation of Particulate Microemboli during Cardiopulmonary Bypass: Experimental and Clinical Studies. Ann. Thorac. Surg. 1992, 54 (6), 1196–1202.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Walpot H.,
    2. Franke R. P.,
    3. Burchard W. G.,
    4. Agternkamp C.,
    5. Müller F. G.,
    6. Mittermayer C.,
    7. Kalff G.

    Particulate Contamination of Infusion Solutions and Drug Additives in the Framework of Long-Term Intensive Therapy. An Animal Model (Article in German). Anaesthesist 1989, 38 (11), 617–621.

    OpenUrlPubMed
31. 31.↵
    1. Jones M. L.,
    2. Warren J. S.

    Monocyte Chemoattractant Protein 1 in a Rat Model of Pulmonary Granulomatosis. Lab. Invest. 1992, 66 (4), 498–503.

    OpenUrlPubMedWeb of Science
32. 32.↵
    1. Bautista A. P.,
    2. Schuler A.,
    3. Spolarics Z.,
    4. Spitzer J. J.

    In Vivo Latex Phagocytosis Primes the Kupffer Cells and Hepatic Neutrophils to Generate Superoxide Anion. J. Leukoc. Biol. 1992, 51 (1), 39–45.

    OpenUrlPubMed
33. 33.↵
    1. Puel V.,
    2. Caudry M.,
    3. Le Métayer P.,
    4. Baste J. C.,
    5. Midy D.,
    6. Marsault C.,
    7. Demeaux H.,
    8. Maire J. P.

    Superior Vena Cava Thrombosis Related to Catheter Malposition in Cancer Chemotherapy Given Through Implanted Ports. Cancer 1993, 72 (7), 2248–2252.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    McCrone Atlas of Microscopic Particles. http://www.mccroneatlas.com (accessed December 28, 2017).
35. 35.↵
    1. Wang W.,
    2. Singh S. K.,
    3. Li N.,
    4. Toler M. R.,
    5. King K. R.,
    6. Nema S.,
    7. et al

    . Immunogenicity of protein aggregates Aggregatest—Concerns and realities. Intl. J. Pharmaceutics. 2012, 431 (1–2), 1–11.

    OpenUrl
36. 36.↵
    Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products. US Food and Drug Administration. Silver Spring, MD. August 2014.
37. 37.↵
    Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. (Draft) EMEA/CHMP/BMWP/14327/2006 Rev. 1. September 24, 2015.
38. 38.↵
    1. Rosenberg A. S.,
    2. Verthelyi D.,
    3. Cherney B. W.

    Managing Uncertainty: A Perspective on Risk Pertaining to Product Quality Attributes as They Bear on Immunogenicity of Therapeutic Proteins. J. Pharm. Sci. 2012, 101 (10), 3560–3567.

    OpenUrlPubMed
39. 39.↵
    1. Hill S. E.,
    2. Heldman L. S.,
    3. Goo E. D.,
    4. Whippo P. E.,
    5. Perkinson J. C.

    Fatal Microvascular Pulmonary Emboli from Precipitation of a Total Nutrient Admixture Solution. 1996, J. Parenter. Enteral. Nutr. 20 (1), 81–87.

    OpenUrlCrossRefPubMed
40. 40.↵
    Intravenous Ceftriaxone and Calcium Drug–Drug Interaction. FDA Drug Safety Newsletter. 2009, 2 (3), 24–25.

    OpenUrl
41. 41.↵
    1. Lehr A. H.,
    2. Brunner J.,
    3. Rangoonwala R.,
    4. Kirkpatrick C. J.

    Particulate Matter Contamination of Intravenous Antibiotics Aggravates Loss of Functional Capillary Density in Postischemic Striated Muscle. Am. J. Respir. Crit. Care. Med. 2002, 165 (4), 514–520.

    OpenUrlCrossRefPubMedWeb of Science
42. 42.↵
    1. Nahri L. O.,
    2. Covari V.,
    3. Ripple D. C.,
    4. Afonina N.,
    5. Cecchini I.,
    6. DeFelippis M. R.,
    7. Garidel P.,
    8. Herre A.,
    9. Koulov A. V.,
    10. Lubiniecki T.,
    11. et al

    . Subvisible (2–100 μm) Particle Analysis during Biotherapeutic Drug Development: Part 1, Considerations and Strategies. J. Pharm. Sci. 2015, 104 (6), 1899–1908.

    OpenUrl
43. 43.↵
    1. Covari V.,
    2. Nahri L. O.,
    3. Spitznagel T. M.,
    4. Afonina N.,
    5. Cao S.,
    6. Cash P.,
    7. Cecchini I.,
    8. DeFelippis M. R.,
    9. Garidel P.,
    10. Herre A.,
    11. et al

    . Subvisible (2–100 μm) Particle Analysis during Biotherapeutic Drug Development: Part 2, Experience With The Application of Subvisible Particle Analysis. Biologicals. 2015, 43 (6), 457–473.

    OpenUrl
44. 44.↵
    1. Gerhardt A.,
    2. Nguyen B. H.,
    3. Lewus R.,
    4. Carpenter J. F.,
    5. Randolph T. W.

    Effect of Siliconization Method on Particle Generation in a Monoclonal Antibody Formulation in Pre-Filled Syringes. J. Pharm. Sci. 2015, 104 (5), 1601–1609.

    OpenUrl
45. 45.↵
    1. Eglovitch J.

    FDA Taking Closer Look at Manufacturers' Visual Testing Programs While USP Would Set New Limits for Particles. The Gold Sheet. October 2013.